CA3099507A1 - Cyclopentane compounds - Google Patents
Cyclopentane compounds Download PDFInfo
- Publication number
- CA3099507A1 CA3099507A1 CA3099507A CA3099507A CA3099507A1 CA 3099507 A1 CA3099507 A1 CA 3099507A1 CA 3099507 A CA3099507 A CA 3099507A CA 3099507 A CA3099507 A CA 3099507A CA 3099507 A1 CA3099507 A1 CA 3099507A1
- Authority
- CA
- Canada
- Prior art keywords
- fluorophenyl
- compound
- amino
- fluoro
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2018/086503 | 2018-05-11 | ||
| CN2018086503 | 2018-05-11 | ||
| PCT/EP2019/061888 WO2019215268A1 (en) | 2018-05-11 | 2019-05-09 | Cyclopentane compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3099507A1 true CA3099507A1 (en) | 2019-11-14 |
Family
ID=66542241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3099507A Pending CA3099507A1 (en) | 2018-05-11 | 2019-05-09 | Cyclopentane compounds |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11274091B2 (https=) |
| EP (1) | EP3790870B1 (https=) |
| JP (1) | JP7418354B2 (https=) |
| KR (1) | KR102806779B1 (https=) |
| CN (1) | CN112424182B (https=) |
| AR (1) | AR115382A1 (https=) |
| AU (1) | AU2019266525B2 (https=) |
| BR (1) | BR112020023065A2 (https=) |
| CA (1) | CA3099507A1 (https=) |
| DK (1) | DK3790870T3 (https=) |
| ES (1) | ES2944735T3 (https=) |
| MX (1) | MX2020012065A (https=) |
| PT (1) | PT3790870T (https=) |
| TW (1) | TWI830733B (https=) |
| UY (1) | UY38229A (https=) |
| WO (1) | WO2019215268A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI830733B (zh) * | 2018-05-11 | 2024-02-01 | 中國大陸商迪哲（江蘇）醫藥有限公司 | 環戊烷化合物 |
| JP7594274B2 (ja) | 2019-10-24 | 2024-12-04 | 国立大学法人大阪大学 | 難聴の予防および／または治療用医薬組成物 |
| WO2025008249A1 (en) | 2023-07-06 | 2025-01-09 | Basf Se | Triazole compounds for the control of invertebrate pests |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004017930A1 (de) | 2004-04-14 | 2005-11-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
| WO2006001958A2 (en) * | 2004-05-21 | 2006-01-05 | Merck & Co., Inc. | Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity |
| EP2049500B1 (en) * | 2006-07-06 | 2011-09-07 | Array Biopharma, Inc. | Cyclopenta [d] pyrimidines as akt protein kinase inhibitors |
| CN102015708B (zh) * | 2008-01-09 | 2014-03-26 | 阵列生物制药公司 | 作为akt蛋白激酶抑制剂的嘧啶基环戊烷 |
| PT2370442E (pt) * | 2008-11-26 | 2013-06-27 | Pfizer | 3-aminociclopentanocarboxamidas como moduladores de receptor de quimiocina |
| US7893099B2 (en) * | 2009-06-11 | 2011-02-22 | Hoffman-La Roche Inc. | Cyclopentane derivatives |
| EP2368876A1 (en) | 2010-03-01 | 2011-09-28 | Sanofi | Derivatives of aminoindanes, their preparation and their application in therapeutics |
| CN105308040B (zh) * | 2013-06-21 | 2019-06-04 | 默克专利股份公司 | 1,3-二氨基环戊烷甲酰胺衍生物 |
| SG11201600726QA (en) * | 2013-07-29 | 2016-03-30 | Merck Patent Gmbh | 1,3-disubstituted cyclopentane derivatives |
| TWI830733B (zh) * | 2018-05-11 | 2024-02-01 | 中國大陸商迪哲（江蘇）醫藥有限公司 | 環戊烷化合物 |
-
2019
- 2019-05-06 TW TW108115491A patent/TWI830733B/zh active
- 2019-05-09 WO PCT/EP2019/061888 patent/WO2019215268A1/en not_active Ceased
- 2019-05-09 MX MX2020012065A patent/MX2020012065A/es unknown
- 2019-05-09 PT PT197241524T patent/PT3790870T/pt unknown
- 2019-05-09 CA CA3099507A patent/CA3099507A1/en active Pending
- 2019-05-09 KR KR1020207035633A patent/KR102806779B1/ko active Active
- 2019-05-09 CN CN201980046444.XA patent/CN112424182B/zh active Active
- 2019-05-09 ES ES19724152T patent/ES2944735T3/es active Active
- 2019-05-09 JP JP2020563695A patent/JP7418354B2/ja active Active
- 2019-05-09 AU AU2019266525A patent/AU2019266525B2/en active Active
- 2019-05-09 DK DK19724152.4T patent/DK3790870T3/da active
- 2019-05-09 EP EP19724152.4A patent/EP3790870B1/en active Active
- 2019-05-09 BR BR112020023065-0A patent/BR112020023065A2/pt unknown
- 2019-05-10 AR ARP190101251A patent/AR115382A1/es unknown
- 2019-05-10 UY UY0001038229A patent/UY38229A/es not_active Application Discontinuation
-
2020
- 2020-11-11 US US17/095,725 patent/US11274091B2/en active Active
-
2021
- 2021-12-27 US US17/562,022 patent/US12378218B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| UY38229A (es) | 2019-11-29 |
| AR115382A1 (es) | 2021-01-13 |
| JP2021523178A (ja) | 2021-09-02 |
| US12378218B2 (en) | 2025-08-05 |
| AU2019266525A1 (en) | 2020-11-26 |
| KR102806779B1 (ko) | 2025-05-12 |
| EP3790870B1 (en) | 2023-04-19 |
| EP3790870A1 (en) | 2021-03-17 |
| BR112020023065A2 (pt) | 2021-02-02 |
| KR20210018287A (ko) | 2021-02-17 |
| PT3790870T (pt) | 2023-05-05 |
| US20210070733A1 (en) | 2021-03-11 |
| CN112424182B (zh) | 2023-05-23 |
| AU2019266525B2 (en) | 2024-06-13 |
| US20220194922A1 (en) | 2022-06-23 |
| JP7418354B2 (ja) | 2024-01-19 |
| MX2020012065A (es) | 2021-02-26 |
| TW202016087A (zh) | 2020-05-01 |
| US11274091B2 (en) | 2022-03-15 |
| ES2944735T3 (es) | 2023-06-23 |
| DK3790870T3 (da) | 2023-05-08 |
| CN112424182A (zh) | 2021-02-26 |
| WO2019215268A1 (en) | 2019-11-14 |
| TWI830733B (zh) | 2024-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3573987B1 (en) | Tyrosine amide derivatives as rho- kinase inhibitors | |
| EP3490982B1 (en) | Pharmaceutical compounds | |
| EP3728225A1 (en) | Substituted indole compounds useful as tlr inhibitors | |
| US12378218B2 (en) | Cyclopentane compounds | |
| EP3773555A1 (en) | Factor xiia inhibitors | |
| KR20200115550A (ko) | 키나제 억제제로서의 아미노피롤로트리아진 | |
| AU2015323380A1 (en) | Methyl-and trifluoromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof | |
| CN116685313A (zh) | 用于治疗神经变性疾病的含有茚满基的羧酸化合物 | |
| WO2016126869A1 (en) | 3,3-difluoro-piperidine derivatives as nr2b nmda receptor antagonists | |
| WO2011083316A1 (en) | Benzazepine derivatives for the treatment of central nervous system disorders | |
| KR20230160901A (ko) | 유비퀴틴 특이 프로테아제 19(usp19)의 억제제로서의 약제학적 화합물 | |
| RU2794997C9 (ru) | Соединения циклопентана | |
| RU2794997C2 (ru) | Соединения циклопентана | |
| HK40047027B (en) | Cyclopentane compounds | |
| HK40047027A (en) | Cyclopentane compounds | |
| HK40047026A (en) | Cyclopentane compounds | |
| TW202448450A (zh) | 磺醯胺及碸的氟化環狀衍生物以及其組成物與方法 | |
| IL323490A (en) | 1-h-pyrrolo[3,2-c]pyridine compounds that act against cancer through menin agonism | |
| WO2026090447A1 (en) | Phosphonic acid and ester compounds and uses thereof | |
| JPWO2021222858A5 (https=) | ||
| HK1234388A1 (en) | Methyl-and trifluoromethyl-substituted pyrrolopyridine modulators of rorc2 an methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20231227 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250221 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250429 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250429 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250613 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250616 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250725 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250725 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D149 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S INTERVIEW Effective date: 20251201 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260304 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260305 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260305 |